Apollo Hospitals Shares Jump to Record on Healthtech Arm Spinoff
The stock jumped as much as 4.7% after it said late Monday it will merge pharmacy business Apollo Healthco Ltd. and wholesale distributor Keimed Pvt. with Apollo Healthtech and list the newly created unit in 18 to 21 months.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
OpenRock S2 Debuts -- Ultra-Light Open-Ear Sports Earbuds Engineered for Comfortable Fit
HONG KONG, July 1, 2025 /PRNewswire/ -- OpenRock, an industry-leading open-ear audio brand, officially launches the OpenRock S2, ultra-light open-ear sports earbuds. Weighing just 7 grams each, it features a secure and lightweight design that delivers high-quality audio while keeping you aware of your surroundings. It has earned praise worldwide from well-known media outlets such as Android Headlines and NeozOne. Key features include: 7g Ultra-Light Hook-Clip Design: Each earbud weighs just 7g, combining an ultra-thin 0.6mm titanium wire and soft liquid silicone for a flexible fit. The ergonomic hook-clip design ensures even pressure distribution for a secure and all-day comfort. Triple Sweat & Water Protection: An angled fit channels sweat away, allowing it to naturally slide off. The independent cavity and waterproof nano-coating protect the internal components. With IPX5 water resistance, it stands up to sweat and light rain with ease. Premium Sound with BassDirect™: The BassDirect™ technology delivers deep, low-distortion bass. Enhanced by the LISO 2.0 algorithm, LDAC codec, and Hi-Res Audio certification, the OpenRock S2 ensures clear, high-fidelity sound. Remote Camera Control: Easily snap photos or start recording videos by pressing the earbud button four times when your phone is in photo or video mode—ideal for hassle-free shooting on the go. Up to 32-Hour Battery Life: Enjoy up to 8 hours on a single charge, and up to 32 hours with the charging case. A 5-minute quick charge provides 1 hour of playback. OpenRock is dedicated to providing an exceptional auditory experience through superior craftsmanship and sound quality. Its innovative open-ear air-conduction design delivers "The Sound of Freedom" – rich bass and clarity – while keeping wearers aware of their surroundings. By seamlessly blending functionality with cutting-edge technology, OpenRock earbuds enable users to enjoy immersive sound—whether they're pursuing an active lifestyle or simply enjoying their favorite music throughout the day. The OpenRock S2 was officially launched on July 1, 2025, at a retail price of $98.99. It is now available for purchase globally via the official OpenRock website and Amazon. View original content to download multimedia: SOURCE OpenRock Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
This Chinese Stock Just Launched Something That Could Be Even Bigger and More Powerful Than DeepSeek
Baidu (BIDU) shares are in focus after the company made its ERNIE large language models (LLMs) open source – effectively enabling the global AI community to use them for R&D. Note that Baidu's ERNIE 4.5 series outperforms DeepSeek's V3 model on a significant number of benchmarks across key capability categories. Elon Musk's Tesla Makes History With 'First Time That a Car Has Delivered Itself to Its Owner' This Defense Stock Could Be the Next Palantir. Should You Buy It Now? Cathie Wood Is Pounding the Table on AMD Stock. Should You Buy Shares Now? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Still, Baidu stock is down some 19% versus its year-to-date high at the time of writing. Baidu shares stand to benefit rather significantly from management's decision to open source ERNIE models. By making its LLMs freely available under the Apache 2.0 license, BIDU invites global developers to build, fine-tune, and deploy on its architecture – accelerating adoption and ecosystem growth. Baidu's move mirrors the success of DeepSeek's open-source strategy, which reshaped China's AI landscape. The open-source release also enhances transparency and trust – potentially attracting enterprise and government partnerships. In short, the announcement positions BIDU as a foundational platform – a shift that could unlock long-term monetization and valuation upside. Baidu stock hasn't been particularly exciting for investors this year, but Miranda Zhuang – a Bank of America analyst – recommends owning it for the long term. Zhuang is bullish on BIDU shares primarily because the Beijing-headquartered firm has already launched fully autonomous vehicle operations in China. Moreover, Baidu is fully committed to expanding its robotaxi services internationally, which she's convinced will drive incremental revenue growth in the years ahead. Integrating artificial intelligence will help BIDU reinvigorate growth in its advertising business as well, according to the BofA analyst. Miranda Zhuang currently has a 'Buy' rating on Baidu shares and a price target of $100, indicating potential upside of another 18% from here. Other Wall Street firms also expect BIDU shares to extend gains as the Chinese tech behemoth continues to tap on artificial intelligence in pursuit of lower costs and higher returns. At the time of writing, the consensus rating on Baidu stock sits at 'Moderate Buy' with the mean target of about $105 indicating potential upside of some 22% from current levels. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Foundation for Sarcoidosis Research Announces Launch of Enhanced Sarcoidosis Data Registry
CHICAGO, July 01, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those affected, is proud to announce the launch of a new and enhanced version of the FSR-SARC Registry, the Sarcoidosis Advanced Registry for Cures. The FSR-SARC Registry is an IRB-approved, longitudinal, patient-powered database designed to accelerate sarcoidosis research by collecting critical insights on diagnosis, organ manifestation, treatments, symptoms, and impacts on quality of life. With nearly 7,000 participants from 68 different countries to date, the Registry is a cornerstone of FSR's mission to advance understanding and treatment of this complex and often misunderstood disease. The upgraded FSR-SARC Registry introduces a new, user-friendly platform (in partnership with Across Healthcare) with expanded features to maximize the impact of patient participation. Participants can now more easily share their experiences, update their information, and contribute to a growing body of knowledge that supports both clinical research and improved patient outcomes. Key Features and Benefits of the New FSR-SARC Registry: Enhanced Data Collection: The registry now captures even more comprehensive information on patients impacted by sarcoidosis. In addition to questionnaires and surveys, participants receiving care in the U.S. can link the Registry directly to their provider's patient portal. Improved Security and Privacy: Hosted on Across Healthcare's HIPAA-compliant platform, the Registry ensures that all personal health information is encrypted, securely stored, and only shared in de-identified form with approved researchers. Empowering Patient Voices: By enabling patients and caregivers to self-report their experiences, the registry provides critical insights into the variability, progression, and burden of sarcoidosis, informing future research and care recommendations. Facilitating Research and Clinical Trials: The registry connects interested patients to IRB-approved research opportunities based on both their eligibility and proximity to trial sites, helping to stimulate hypothesis-driven research and support the development of new treatments. Commitment to Representation and Access: FSR remains dedicated to expanding the variety of Registry participants and ensuring representation of all sarcoidosis patients. 'FSR is committed to empowering patients and accelerating research through the FSR-SARC Registry. We are immensely grateful for the extraordinary commitment of the sarcoidosis community in giving of their time and insights to inform and drive sarcoidosis research,' said Mary McGowan, President and CEO of FSR. 'Now in its tenth year, the Registry has been one of our most powerful tools to elevate patient voices in the advancement of sarcoidosis research. The enhanced surveys and platform represent a significant step forward in our efforts to drive innovation elevate patient-centered drug development, and improve patient outcomes for all impacted by sarcoidosis.' Participation in the FSR-SARC Registry is voluntary, confidential, and open to all individuals living with sarcoidosis or their caregivers. By joining, participants help shape the future of sarcoidosis research and care. For more information about the FSR-SARC Registry and to sign up, please visit About Sarcoidosis Sarcoidosis is a rare inflammatory disease characterized by granulomas—tiny clumps of inflammatory cells—that can form in one or more organs. 90% of patients living with sarcoidosis have lung involvement. Despite advances in research, sarcoidosis remains challenging to diagnose, with limited treatment options and no known cure. Approximately 175,000 people live with sarcoidosis in the United States. About the Foundation for Sarcoidosis Research The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those living with the disease through research, education, and support. For more information about FSR and its community programs, visit: Media Contact: Cathi Davis, Director of Communications and Marketing Foundation for Sarcoidosis Research cathi@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
